

- [51] Zhang JX, Han L, Bao ZS, Wang YY, Chen LY, Yan W, Yu SZ, Pu PY, Liu N, You YP, *et al.* HOTAIR, a cell cycle-associated long noncoding RNA and a strong predictor of survival, is preferentially expressed in classical and mesenchymal glioma. *Neuro-oncology* 2013; 15(12): 1595-1603.
<http://dx.doi.org/10.1093/neuonc/not131>
- [52] Lamba G, Gupta R, Lee B, Ambrale S, Liu D. Current management and prognostic features for gastrointestinal stromal tumor (GIST). *Experimental hematology & oncology* 2012; 1(1): 14.
- [53] Gregory TK, Wald D, Chen Y, Vermaat JM, Xiong Y, Tse W. Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics. *J Hematol Oncol* 2009; 2: 23.
<http://dx.doi.org/10.1186/1756-8722-2-23>
- [54] He H, Hua X, Yan J. Epigenetic regulations in hematopoietic Hox code. *Oncogene* 2011; 30(4): 379-88.
<http://dx.doi.org/10.1038/onc.2010.484>
- [55] Shan B, Yao TP, Nguyen HT, Zhuo Y, Levy DR, Klingsberg RC, Tao H, Palmer ML, Holder KN, Lasky JA. Requirement of HDAC6 for transforming growth factor-beta1-induced epithelial-mesenchymal transition. *J Biol Chem* 2008; 283(30): 21065-73.
<http://dx.doi.org/10.1074/jbc.M802786200>
- [56] Li C, Nguyen HT, Zhuang Y, Lin Y, Flemington EK, Guo W, Guenther J, Burow ME, Morris GF, Sullivan D, *et al.* Post-transcriptional up-regulation of miR-21 by type I collagen. *Mol Carcinog* 2011; 50(7): 563-70.
<http://dx.doi.org/10.1002/mc.20742>
- [57] Nguyen HT, Zhuang Y, Sun L, Kantrow SP, Kolls JK, You Z, Zhuo Y, Shan B. Src-mediated morphology transition of lung cancer cells in three-dimensional organotypic culture. *Cancer Cell Int* 2013; 13(1): 16.
<http://dx.doi.org/10.1186/1475-2867-13-16>
- [58] Antoon JW, Lai R, Struckhoff AP, Nitschke AM, Elliott S, Martin EC, Rhodes LV, Yoon NS, Salvo VA, Shan B, *et al.* Altered death receptor signaling promotes epithelial-to-mesenchymal transition and acquired chemoresistance. *Sci Rep* 2012; 2: 539.
<http://dx.doi.org/10.1038/srep00539>
- [59] Zavadil J, Narasimhan M, Blumenberg M, Schneider RJ. Transforming growth factor-beta and microRNA: mRNA regulatory networks in epithelial plasticity. *Cells, tissues, organs* 2007; 185(1-3): 157-61.
<http://dx.doi.org/10.1159/000101316>
- [60] Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, Bentwich Z, Oren M. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. *Mol Cell* 2007; 26(5): 731-43.
<http://dx.doi.org/10.1016/j.molcel.2007.05.017>
- [61] Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ, *et al.* Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. *Mol Cell* 2007; 26(5): 745-52.
<http://dx.doi.org/10.1016/j.molcel.2007.05.010>
- [62] Budhu A, Ji J, Wang XW. The clinical potential of microRNAs. *J Hematol Oncol* 2010; 3: 37.
<http://dx.doi.org/10.1186/1756-8722-3-37>
- [63] Zhang H, Chen Z, Wang X, Huang Z, He Z, Chen Y. Long non-coding RNA: a new player in cancer. *J Hematol Oncol* 2013; 6: 37.
<http://dx.doi.org/10.1186/1756-8722-6-37>
- [64] Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. *Cell* 2009; 139(5): 871-90.
<http://dx.doi.org/10.1016/j.cell.2009.11.007>
- [65] Wu CY, Tsai YP, Wu MZ, Teng SC, Wu KJ. Epigenetic reprogramming and post-transcriptional regulation during the epithelial-mesenchymal transition. *Trends Genet* 2012; 28(9): 454-63.
<http://dx.doi.org/10.1016/j.tig.2012.05.005>
- [66] Frisch SM, Schaller M, Cieply B. Mechanisms that link the oncogenic epithelial-mesenchymal transition to suppression of anoikis. *Journal of cell science* 2013; 126(Pt 1): 21-29.
<http://dx.doi.org/10.1242/jcs.120907>
- [67] Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer. role of phosphatidylinositol 3' kinase/AKT pathways. *Oncogene* 2005; 24(50): 7443-54.
<http://dx.doi.org/10.1038/sj.onc.1209091>
- [68] Prensner JR, Iyer MK, Balbin OA, Dhanasekaran SM, Cao Q, Brenner JC, Laxman B, Asangani IA, Grasso CS, Kominsky HD, *et al.* Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. *Nature biotechnology* 2011; 29(8): 742-49.
<http://dx.doi.org/10.1038/nbt.1914>
- [69] Arita T, Ichikawa D, Konishi H, Komatsu S, Shiozaki A, Shoda K, Kawaguchi T, Hirajima S, Nagata H, Kubota T, *et al.* Circulating Long Non-coding RNAs in Plasma of Patients with Gastric Cancer. *Anticancer research* 2013; 33(8): 3185-3193.
- [70] Crea F, Fornaro L, Bocci G, Sun L, Farrar WL, Falcone A, Danesi R. EZH2 inhibition. targeting the crossroad of tumor invasion and angiogenesis. *Cancer metastasis reviews* 2012; 31(3-4): 753-61.
<http://dx.doi.org/10.1007/s10555-012-9387-3>
- [71] Gutierrez SE, Romero-Oliva FA. Epigenetic changes: a common theme in acute myelogenous leukemogenesis. *J Hematol Oncol* 2013; 6: 57.
<http://dx.doi.org/10.1186/1756-8722-6-57>
- [72] Li CH, Chen Y. Targeting long non-coding RNAs in cancers. progress and prospects. *The international journal of biochemistry & cell biology* 2013; 45(8): 1895-1910.
<http://dx.doi.org/10.1016/j.biocel.2013.05.030>
- [73] Zhao J, Ohsumi TK, Kung JT, Ogawa Y, Grau DJ, Sarma K, Song JJ, Kingston RE, Borowsky M, Lee JT. Genome-wide identification of polycomb-associated RNAs by RIP-seq. *Mol Cell* 2010; 40(6): 939-53.
<http://dx.doi.org/10.1016/j.molcel.2010.12.011>
- [74] Zhang LF, Huynh KD, Lee JT. Perinucleolar targeting of the inactive X during S phase: evidence for a role in the maintenance of silencing. *Cell* 2007; 129(4): 693-706.
<http://dx.doi.org/10.1016/j.cell.2007.03.036>
- [75] He A, Shen X, Ma Q, Cao J, von Gise A, Zhou P, Wang G, Marquez VE, Orkin SH, Pu WT. PRC2 directly methylates GATA4 and represses its transcriptional activity. *Genes Dev* 2012; 26(1): 37-42.
<http://dx.doi.org/10.1101/gad.173930.111>
- [76] Gutschner T, Hammerle M, Diederichs S. MALAT1 -- a paradigm for long noncoding RNA function in cancer. *Journal of molecular medicine* 2013; 91(7): 791-801.
<http://dx.doi.org/10.1007/s00109-013-1028-y>